FibroGen receives China SAMR approval for sale of China business to AstraZeneca; closing expected in Q3 2025

KYNTRA BIO, INC.

China State Administration for Market Regulation decided not to prohibit AstraZeneca's acquisition of FibroGen China.
Transaction includes all equity of FibroGen International (Hong Kong) Ltd. and roxadustat assets in China.
Closing expected in Q3 2025, subject to customary closing conditions and deliverables.
FibroGen retains roxadustat rights in US, Canada, Mexico, and other non-AstraZeneca/Astellas territories.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.